Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theriva Biologics ( (TOVX) ) just unveiled an announcement.
Theriva Biologics, Inc. announced the date for its 2025 Annual General Meeting of Shareholders, set for August 29, 2025. The company has revised deadlines for stockholder proposals and director nominations due to the meeting being scheduled more than 30 days prior to the anniversary of the previous year’s meeting. Proposals to be included in the proxy materials must be submitted by July 5, 2025, and stockholders intending to solicit proxies for director nominees must also comply with the new deadline.
The most recent analyst rating on (TOVX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Average Trading Volume: 1,414,492
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.89M
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.